- /
- Supported exchanges
- / US
- / CDT.NASDAQ
Conduit Pharmaceuticals Inc. (CDT NASDAQ) stock market data APIs
Conduit Pharmaceuticals Inc. Financial Data Overview
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Conduit Pharmaceuticals Inc. data using free add-ons & libraries
Get Conduit Pharmaceuticals Inc. Fundamental Data
Conduit Pharmaceuticals Inc. Fundamental data includes:
- Net Revenue:
- EBITDA: -24 738 000
- Earnings Per Share: -1 177
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
Get Conduit Pharmaceuticals Inc. Earnings data
Corporate Events Calendar & News package for
What’s included:
- Latest Release: 2025-12-31
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Conduit Pharmaceuticals Inc. News
New
CDT Equity Inc. Announces Receipt of Nasdaq Deficiency Letter
NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 28, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announced that the Company received a written notic...
CDT Equity Inc. Announces Receipt of Nasdaq Deficiency Letter
NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 28, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announced that the Company received a written notice ...
CDT Announces Canadian Patent for AZD5904 in Male Infertility
NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 27, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announces that the patent covering the use of AZD5904...
CDT Equity Advances AstraZeneca PLC (AZN)’s AZD5904 Into PCT Patent Protection Stage
We recently compiled a list of the 10 Best Cancer Stocks to Buy for the Long Term. AstraZeneca PLC is among the best cancer stocks on this list. TheFly reported on May 6 that CDT Equity announced tha...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.